An observational study in Ulcerative Colitis, sponsored by Imelda GI Clinical Research Center. Completed at 1 site in Belgium. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-04.
Sponsored by Imelda GI Clinical Research Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Colitis, Ulcerative with a site in Belgium — 26 open to participants now, 50 under way, 27 of them phase 3. Colitis, Ulcerative · Belgium.
Among the 187 studies in Colitis, Ulcerative with a site in Belgium, this one is the 18th largest by enrollment of the 19 observational ones that give a count, is one of 7 that started in 2020, is one of 19 observational ones, and was the 136th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →26 of the 187 studies in Colitis, Ulcerative with a site in Belgium are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Belgium, United States, Germany and 2 more countries
Ages 18–60
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Sanofi · Sites in Belgium, United States, Argentina and 28 more countries
Ages 16–80
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 71 · Phase 3 82 · Phase 4 11
First in 2003; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is below the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 198 across the 168 interventional studies, 280 across the 19 observational. Of the 134 that completed or were terminated, 80 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
160 of 187 have an industry lead sponsor. The 10 most frequent:
Imelda GI Clinical Research Center is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Imelda GI Clinical Research Center has 4 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
12 of the studies in Colitis, Ulcerative with a site in Belgium that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 187 studies in Colitis, Ulcerative with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background and rationale:
In ulcerative colitis, treating beyond endoscopic healing has shown a reduction of relapse and hospitalization, pushing for histological remission in daily clinical practice.1 However, very little is known on how histological remission is associated with patient reported outcomes (PROMs).2,3 In recent years, several questionnaires have been developed to assess what really matters to patients: symptoms and the burden UC exerts on them.4 As PROMs are getting more and more attention during drug development programs and drug approval by international organizations, including FDA and EMA, the link between objective outcome measures (endoscopic, histological, biochemical) and PROMs should therefore be better characterized.
Objectives and design:
To investigate prospectively the association of patient reported outcomes (PROMs) and biochemical, endoscopic and histological outcome measures in patients with ulcerative colitis.
After informed consent, patients will undergo endoscopic assessment evaluating endoscopic disease activity using established scoring systems
Endoscopic response according to
IBD disk remission per item:
Patient with ulcerative colitis and planned endoscopy as part of routine care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients with ulcerative colitis (≥ 16 years) undergoing planned endoscopic assessment as part of standard of care between 01.07.2020 and 30.06.2021. Evidence of a personally signed and dated document (ICF) indicating that the subject has been informed of all aspects of the study.
EXCLUSION CRITERIA:
Subjects with a diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or Crohn's disease.
Subjects with clinical findings suggestive of CD (e.g. fistulae, granulomas on ) are also excluded. Similar data collection within 8 weeks prior to endoscopic assessment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with ulcerative colitis and planned endoscopy as part of routine care
Diagnostic Test: endoscopic biopsies
patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
correlation between histological disease activity and disability
histological activity is based on the Nancy score, disability is based on the IBD disk
Time frame: 1 day
correlation between histological disease activity and patient reported outcomes
histological activity is based on the Nancy score, PRO is based on the SCCAI
Time frame: 1 day
correlation between histological disease activity and patient reported outcomes
histological activity is based on the Nancy score, PRO is based on the VAS
Time frame: 1 day
correlation between histological disease activity and patient reported outcomes
histological activity is based on the Nancy score, PRO is based on the PRO-2
Time frame: 1 day
correlation between histological disease activity and endoscopic disease activity
histological activity is based on the Nancy score, endoscopic disease activityis based on the Mayo endoscopic subscore
Time frame: 1 day
correlation between histological disease activity and endoscopic disease activity
histological activity is based on the Nancy score, endoscopic disease activity is based on the UCEIS
Time frame: 1 day
correlation between histological disease activity and biomarkers
histological activity is based on the Nancy score, biomarkers (CRP, hemoglobine, albumin)
Time frame: 1 day
correlation between histological disease activity and patient reported outcomes
histological activity is based on the Nancy score, disability is based on the IBD control in case of non remission
Time frame: 1 day
Plan to share: Undecided — up on request
Ran from Jul 2020 to primary completion in Jul 2021, 12 months.
Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's 12 months is below that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imelda GI Clinical Research Center